secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001171843-23-005595
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024
-----------------------------------------------------------------------

- FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.
- Enrollment of relapsed PTCL patients with ≤3 prior therapies; initiation expected in Q1 2024.
- Company to host conference call on Sept 7, 2023 to discuss trial plan and business updates.
- Soquelitinib is a selective ITK inhibitor; potential in hematologic cancers, solid tumors, autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/0001171843-23-005595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/f8k_090623.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer